title: PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.
authors.affiliation: Department of Medicine, Baylor College of Medicine, Houston, TX, USA. redfield.margaret@mayo.edu
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Redfield
authors.forename: Barry A
authors.initials: BA
authors.lastname: Borlaug
authors.forename: Greg D
authors.initials: GD
authors.lastname: Lewis
authors.forename: Selma F
authors.initials: SF
authors.lastname: Mohammed
authors.forename: Marc J
authors.initials: MJ
authors.lastname: Semigran
authors.forename: Martin M
authors.initials: MM
authors.lastname: Lewinter
authors.forename: Anita
authors.initials: A
authors.lastname: Deswal
authors.forename: Adrian F
authors.initials: AF
authors.lastname: Hernandez
authors.forename: Kerry L
authors.initials: KL
authors.lastname: Lee
authors.forename: Eugene
authors.initials: E
authors.lastname: Braunwald
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D015150:Echocardiography, Doppler; D005080:Exercise Test; D017079:Exercise Tolerance / Q000187:drug effects*; D054144:Heart Failure, Diastolic / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D010101:Oxygen Consumption / Q000187:drug effects; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use; D020127:Recovery of Function; D012107:Research Design; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D002317:Cardiovascular Agents; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate